Pharmacogenetics of Acenocoumarol

University Hospitals (UH)

Status: Completed

Conditions: Thromboembolic Diseases

Study type: Observational

Funder types: Other

Identifiers

NCT01492777

CER 08-019

Details and patient eligibility

About

The use of oral anticoagulation is marked by an elevated risk of adverse drug events (ADE) due to a narrow therapeutic window leading to important medical and economical consequences. The risk of ADE is increased partly by drug interactions and recently identified genetic factors influencing the metabolism of coumarins (polymorphism of the cytochrome P450 CYP2C9) as well as the target enzyme of the coumarins (polymorphism of the vitamin K epoxide reductase complex subunit 1 (VKORC1).

The objective is to determine the impact of several genotypes on acenocoumarol treatment and on vulnerability to drug-drug interactions.

Enrollment: 115 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Every patients with requiring acenocoumarol therapy for at least 4 weeks and a target INR in the low intensity range (INR range 2-3)
• Age ≥ 18 years
• Signed informed consent

Exclusion criteria

• Severe cognitive impairment
• Previous or current treatment with any coumarin